

// ()
//
// , ,

*

, :

, ,

, :

()

()

CCI

5-7×10 L/m² - 10×10 L/m²

:

, :

, :

:

HLA

.(-)

.()

HLA

* /L

(%) HLA

%

(%) %

- * /L

.(-)

*

%

$$\times (\frac{\quad - \quad}{10^{11} \times}) = CCI$$

10¹¹ ×

HLA-DR

* /L CCI
- - * /L

HLA

% - .()

:

HLA

)

)

(

(

$$(\quad)$$

—

CCI

%

)

(

$P < /$

$$\left(\frac{\%}{\%} \right) \cdot \left(\frac{P < /}{P < /} \right) \left(\frac{\%}{\% /} \right)$$

()

%

%

.()

% /

%

()

% /

REFERENCES

2. Barz D, Staack D, Lehmann R, Stange K, Schnurstein K. Antibody formation after filtered blood cell replacement in hematologic-oncologic patients. *Beitr Infusionsther Transfusionsmed* 1996; 33: 30-4.
3. Balducci L, Benson K, Lyman GH, Sanderson R, Fields K, Ballester OF, et al. Cost-effectiveness of white cell-reduction filters in treatment of adult acute myelogenous leukemia. *Transfusion* 1993; 33(8): 665-70.
4. Hoffman R. *Hematology: Basic principles and practice*. USA: Churchill Livingstone, 1991.
5. Sniecinski I, O'Donnell MR, Nowicki B, Hill LR. Prevention of refractoriness and HLA-alloimmunization using filtered blood products. *Blood* 1988; 71(5): 1402-7.